The European Genomic Medicine Consortium (EGMEDC)

Who We Are

The European Genomic Medicine Consortium (EGMEDC) is a collaborative, pan-European non-profit initiative established by CRISPR Medicine News (CMN).

We bring together leaders from clinical practice, infrastructures, academia, industry, regulatory bodies and patient organisations to accelerate the development and delivery of CRISPR and other types of genetic therapies across Europe.

------

Our Mission

We aim to build a coordinated, ethical, and sustainable ecosystem that supports the clinical translation of genetic medicines - ensuring they reach patients in a timely, safe, and equitable manner.

------

What We Do

At EGMEDC, we serve as a unifying force across the gene and cell therapy landscape by:

• Driving Clinical Coordination - Monitoring and facilitating cross-border clinical trials.
• Mapping Infrastructure - Connecting Europe’s diverse genetic screening, cell, and gene therapy capabilities.
• Shaping Policy & Regulation - Advancing harmonized frameworks for ethics, health technology assessment (HTA), and EMA regulatory pathways.
• Enabling Access & Reimbursement - Supporting fair and scalable access strategies across EU member states.
• Fostering Collaboration - Bridging biotech, academia, national health programs, and European research initiatives.
• Engaging Patients and the Public - Promoting transparency, trust, and co-creation through structured dialogue with patient communities and the broader public.
• Convening the Community - Hosting our annual meeting at CRISPRMED, Europe’s premier genomic medicine conference in Copenhagen, Denmark.

------

What’s Next

More details about our founding members and strategic partnerships will be shared soon.

Join us as we together shape the future of genetic medicine in Europe.